SynAct Pharma raises 37 MSEK

(Lund, develops treatments for autoimmune and inflammatory diseases): Has raised 37 MSEK in a funding round from Hunter Capital, Sanos Group, Johannes Schildt, and Thomas Ringberg, and secured a 30 MSEK credit facility from Hunter Capital with member Milad Pournouri. “The data collected so far points to a major shift in how we help the body resolve excessive or chronic inflammation,” comments Jeppe Øvlesen, CEO at SynAct Pharma.